Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 211

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 211
---
    102

(a)(2) Financial Statement Schedules

All financial statement schedules have been omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and accompanying notes included in this report.

(a)(3) Exhibits.

Exhibits not filed or furnished herewith are incorporated by reference to exhibits previously filed with the SEC, as reflected in the table below. We will furnish a copy of any exhibit to stockholders, without charge upon written request to Lineage Cell Therapeutics, Inc., Attention: Corporate Secretary, 2173 Salk Avenue, Suite 200 Carlsbad, CA 92008, or by calling (442) 287-8990.

    Incorporation by Reference

    ExhibitNumber
     
    Description
     
    ExhibitNumber
     
    Filing
     
    Filing Date
     
    File No.

    PLANS OF ACQUISITION

    2.01^
     
    Agreement and Plan of Merger dated November 7, 2018, among Registrant, Patrick Merger Sub, Inc. and Asterias Biotherapeutics, Inc. (“Asterias”)
     
    2.1
     
    8-K
     
    November 8, 2018
     
    001-12830

    ARTICLES OF INCORPORATION AND BYLAWS

    3.01
     
    Restated Articles of Incorporation, as amended
     
    3.1
     
    10-Q
     
    May 10, 2018
     
    001-12830

    3.02
     
    Certificate of Ownership
     
    3.1
     
    8-K
     
    August 12, 2019
     
    001-12830

    3.03
     
    Amended and Restated Bylaws
     
    3.1(a)
     
    8-K
     
    June 13, 2024
     
    001-12830

    INSTRUMENTS DEFINING RIGHTS OF SECURITY HOLDERS

    4.01
     
    Specimen of Common Share Certificate

    S-1
     
    December 18, 1991
     
    033-44549

    4.02*
     
    Description of Capital Stock of the Registrant

    4.03(a)
     
    Form of Common Stock Purchase Warrant issued pursuant to the Securities Purchase Agreement dated November 19, 2024,